

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

07 Jul 2026

### A comparison of vaginal misoprostol and vaginal evening primrose oil in first trimester termination

#### Protocol summary

##### Study aim

Comparison of the effect of vaginal mizemprostol and evening primrose oil in terminating pregnancy in the first trimester of pregnancy up to 14 weeks

##### Design

Clinical trial, with parallel groups, simple randomized, on 72 patients.

##### Settings and conduct

First, to all pregnant patients who refer to Shahid Beheshti Hospital for termination of pregnancy in the first trimester to 14 weeks and are candidates for termination of pregnancy due to Legal Abortion, Missed Abortion, Heart failure, Genetic anomalies. Complete explanations on how to perform them for the patient. It is explained, then the patient's consent to work is obtained, which is attached to the file.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Pregnant women go to Beheshti Hospital for up to 14 weeks to terminate their pregnancy for the reasons mentioned. Exclusion criteria: Uncontrolled seizures, uncontrolled blood pressure, chronic lung disease, mitral valve stenosis, history of known prostaglandin E1 allergy

##### Intervention groups

Vaginal misoprostol and vaginal evening primrose oil are divided into two groups. To a group of prostaglandin E1 (misoprostol) made in Iran, the active ingredient of which is 200 micrograms. Initial dose Initially 600 micrograms (three pills 200 micrograms) The next doses, if needed at intervals of 6 hours, repeat two vaginal pills with a maximum dose of 6 pills. To the second group, 1000 mg vaginal capsule of evening primrose oil in the posterior fornix of the vagina, which is repeated 1000 mg six hours later. Vaginal capsule of evening primrose from Barij company made in Iran

##### Main outcome variables

Number of misoprostol tablets prescribed and number of soft gels of evening primrose oil, uterine and fetal abnormalities, placental retention, time interval to

excretion of products, fever complication

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20201218049749N1**

Registration date: **2021-02-05, 1399/11/17**

Registration timing: **retrospective**

Last update: **2021-02-05, 1399/11/17**

Update count: **0**

##### Registration date

2021-02-05, 1399/11/17

##### Registrant information

##### Name

Maryam Mousavi Shirazi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 31 5550 0111

##### Email address

mousavishirazi-m@mail.kaums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-07-23, 1398/05/01

##### Expected recruitment end date

2019-10-23, 1398/08/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

### Scientific title

A comparison of vaginal misoprostol and vaginal evening primrose oil in first trimester termination

### Public title

A comparison of vaginal misoprostol and vaginal evening primrose oil

### Purpose

Treatment

### Inclusion/Exclusion criteria

#### Inclusion criteria:

Pregnant women go to Beheshti Hospital for up to 14 weeks to terminate their pregnancy

#### Exclusion criteria:

Uncontrolled seizures  
Uncontrolled blood pressure  
Chronic lung disease  
Mitral valve stenosis  
History of known allergy to prostaglandin E1  
Inflammatory bowel disease  
Sensitivity to evening primrose  
Coagulation disease  
Schizophrenia and phenothiazine use  
Cone biopsy of the cervix  
Smoking and supplements

### Age

No age limit

### Gender

Female

### Phase

3

### Groups that have been masked

No information

### Sample size

Target sample size: 72

### Randomization (investigator's opinion)

Randomized

### Randomization description

Block random, individual and using a table of random numbers were divided into two groups. Patients are completely randomly divided into two groups: vaginal misoprostol and vaginal evening primrose oil. In this method, a number of cards or letters selected by the researcher as the first group and the same number of cards for the next groups are considered; Then, by merging the cards together (flipping the cards), a card is taken out and its allocation is recorded, and that card is returned to the other cards after being taken out. The cards are then merged again and another card is removed. This process continues until a random sequence according to the sample size is reached.

### Blinding (investigator's opinion)

Not blinded

### Blinding description

### Placebo

Not used

### Assignment

Parallel

### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics Committee of Kashan University of Medical Sciences

##### Street address

Qutb Ravandi Boulevard, Nursing Boulevard, School of Nursing and Midwifery

##### City

Kashan

##### Province

Isfahan

##### Postal code

8715988141

#### Approval date

2020-11-11, 1399/08/21

#### Ethics committee reference number

IR.KAUMS.MEDNT.REC.1399.142

## Health conditions studied

### 1

#### Description of health condition studied

Spontaneous abortion

#### ICD-10 code

O03.0

#### ICD-10 code description

Genital tract and pelvic infection following incomplete spontaneous abortion

## Primary outcomes

### 1

#### Description

Spontaneous abortion

#### Timepoint

First and 6 hours and 12 hours after taking the drug

#### Method of measurement

Complete disposal of pregnancy products

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

First intervention group : The effect of vaginal misoprostol, with Iranian brand and made in Iran, whose effective ingredient is 200 micrograms. Initial dose Initially 600 micrograms (three pills 200 micrograms) The next doses, if needed at intervals of 6 hours, repeat two vaginal pills with a maximum dose of 6 pills.

#### Category

Treatment - Drugs

## 2

### Description

Second intervention group: The effect of vaginal evening primrose oil, with Barij brand of essential oil and made in Iran, with a dose of 1000 mg in the posterior vagina fornix, which is repeated six hours after 1000 mg.

### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

**Name of recruitment center**

Shahid Beheshti Hospital, Kashan

**Full name of responsible person**

Fatemeh Foroozan Fard

**Street address**

Qotb Ravandi Boulevard-Nurse Boulevard

**City**

Kashan

**Province**

Isfahan

**Postal code**

8715988141

**Phone**

+98 31 5550 0026

**Email**

fatemehforoozanfard@yahoo.com

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**

Kashan University of Medical Sciences

**Full name of responsible person**

Fatemeh Foroozan Fard

**Street address**

Qotb Ravandi Boulevard-Nurse Boulevard

**City**

Kashan

**Province**

Isfahan

**Postal code**

8715988141

**Phone**

+98 31 5555 0026

**Email**

fatemehforoozanfard@yahoo.com

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Kashan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

## Person responsible for general inquiries

### Contact

**Name of organization / entity**

Kashan University of Medical Sciences

**Full name of responsible person**

Maryam Mousavi Shirazi

**Position**

Associate professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

General Practitioner

**Street address**

Qotb Ravandi Boulevard-Nurse Boulevard

**City**

Kashan

**Province**

Isfahan

**Postal code**

8715988141

**Phone**

+98 31 5555 0026

**Email**

pegahmousavi60@gmail.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Kashan University of Medical Sciences

**Full name of responsible person**

Maryam Mousavi Shirazi

**Position**

Non-faculty specialist physician

**Latest degree**

Specialist

**Other areas of specialty/work**

General Practitioner

**Street address**

Qotb Ravandi Blvd., Parstar Blvd., Kashan University of Medical Sciences

**City**

Kashan

**Province**

Isfahan

**Postal code**

8715988141

**Phone**

+98 31 5550 0111

**Fax**

**Email**

mousavishirazi-m@mail.kaums.ac.ir

**Person responsible for updating data****Contact****Name of organization / entity**

Kashan University of Medical Sciences

**Full name of responsible person**

Maryam Mousavi Shirazi

**Position**

Non-faculty specialist physician

**Latest degree**

Specialist

**Other areas of specialty/work**

General Practitioner

**Street address**

Qotb Ravandi Blvd., Parstar Blvd., Kashan University of Medical Sciences

**City**

Kashan

**Province**

Isfahan

**Postal code**

8715988141

**Phone**

+98 31 5550 0111

**Fax****Email**

mousavishirazi-m@mail.kaums.ac.ir

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

Part of the data, such as information about the main outcome or the like, can be shared.

**When the data will become available and for how long**

Access period starts from 2020

**To whom data/document is available**

Researchers working in academic institutions

**Under which criteria data/document could be used**

To review and study more information

**From where data/document is obtainable**

Mail address

**What processes are involved for a request to access data/document**

The request will be sent by e-mail with the address and details of the researcher, after review, to the e-mail address of the requesting information.

**Comments**